Neuropeptides
Volume 43, Issue 5 , Pages 371-385 , October 2009

Effects of TRH and its analogues on primary cortical neuronal cell damage induced by various excitotoxic, necrotic and apoptotic agents

  • D. Jantas

      Affiliations

    • Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, PL 31-343 Krakow, Poland
    • Corresponding Author InformationCorresponding author. Tel.: +48 12 6623368; fax: +48 12 6374500.
    • ,
  • L. Jaworska-Feil

      Affiliations

    • Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, PL 31-343 Krakow, Poland
    • ,
  • A.W. Lipkowski

      Affiliations

    • Center of Experimental and Clinical Medicine, Polish Academy of Sciences, Pawinskiego 5, PL 02-106 Warsaw, Poland
    • ,
  • W. Lason

      Affiliations

    • Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, PL 31-343 Krakow, Poland

Received 17 March 2009 ,Accepted 18 July 2009.

References 

  1. Aberg ND, Brywe KG, Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. Scient. World J. 2006;6:53–80
  2. Allen JW, Vicini S, Faden AI. Exacerbation of neuronal cell death by activation of group I metabotropic glutamate receptors: role of NMDA receptors and arachidonic acid release. Exp. Neurol. 2001;169:449–460
  3. Beart PM, Lim ML, Chen B, Diwakarla S, Mercer LD, Cheung NS, et al. Hierarchical recruitment by AMPA but not staurosporine of pro-apoptotic mitochondrial signaling in cultured cortical neurons: evidence for caspase-dependent/independent cross-talk. J. Neurochem. 2007;103:2408–2427
  4. Behrmann DL, Bresnahan JC, Beattie MS. Modeling of acute spinal cord injury in the rat: neuroprotection and enhanced recovery with methylprednisolone, U-74006F and YM-14673. Exp. Neurol. 1994;126:61–75
  5. Borlongan CV, Stahl CE, Redei E, Wang Y. Prepro-thyrotropin-releasing hormone 178–199 exerts partial protection against cerebral ischemia in adult rats. Neuroreport. 1999;10:3501–3505
  6. Borsello T, Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr. Pharm. Des. 2007;13:1875–1886
  7. Brady KD, Wagner KA, Tashjian AH, Golan DE. Alterations in the frequency and shape of Ca2+ fluctuations in GH4C1 cells induced by thyrotropin-releasing hormone and Bay K 8644. Biochem. J. 1995;306:399–406
  8. Brewer GJ. Serum-free B27/neurobasal medium supports differentiated growth of neurones from the striatum, substantia nigra, septum, cerebral cortex, cerebellum and dentate gyrus. J. Neurosci. Res. 1995;42:674–683
  9. Cheng HY, Hsieh MT, Wu CR, Tsai FH, Lu TC, Hsieh CC, et al. Schizandrin protects primary cultures of rat cortical cells from glutamate-induced excitotoxicity. J. Pharmacol. Sci. 2008;107:21–31
  10. Domin H, Kajta M, Smiałowska M. Neuroprotective effects of MTEP, a selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures. Pharmacol. Rep. 2006;58:846–858
  11. Donnelly-Roberts DL, Xue IC, Arneric SP, Sullivan JP. In vitro neuroprotective properties of the novel cholinergic channel activator(ChCA), ABT-418. Brain Res. 1996;719:36–44
  12. Drmota T, Milligan G. Kinetic analysis of the internalization and recycling of [3H]TRH and C-terminal truncations of the long isoform of the rat thyrotropin-releasing hormone receptor-1. Biochem. J. 2000;346:711–718
  13. Ebihara S, Akaike N. Potassium currents operated by thyrotrophin-releasing hormone in dissociated CA1 pyramidal neurons of rat hippocampus. J. Physiol. 1993;472:689–710
  14. Faden AI, O’Leary DM, Fan L, Bao W, Mullins PG, Movsesyan VA. Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury in vitro and improves of outcome after brain trauma. Exp. Neurol. 2001;167:435–444
  15. Faden AI, Fox GB, Di X, Knoblach SM, Cernak I, Mullins P, et al. Neuroprotective and nootropic actions of a novel cyclized dipeptide after controlled cortical impact injury in mice. J. Cereb. Blood Flow Metab. 2003;23:355–363
  16. Faden AI, Knoblach SM, Cernak I, Fan L, Vink R, Araldi GL, et al. Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo. J. Cereb. Blood Flow Metab. 2003;23:342–354
  17. Faden AI, Knoblach SM, Movsesyan VA, Lea PM, Cernak I. Novel neuroprotective tripeptides and dipeptides. Ann. NY Acad. Sci. 2005;1053:472–481
  18. Faden AI, Movsesyan VA, Knoblach SM, Ahmed F, Cernak I. Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacology. 2005;49:410–424
  19. Faden AI, Stoica B. Neuroprotection: challenges and opportunities. Arch. Neurol. 2007;64:794–800
  20. Frandsen A, Schousboe A. Excitatory amino acid-mediated cytotoxicity and calcium homeostasis in cultured neurons. J. Neurochem. 1993;60:1202–1211
  21. Gershengorn MC, Osman R. Molecular and cellular biology of thyrotropin-releasing hormone receptors. Physiol. Rev. 1996;76:175–191
  22. Greber S, Schwarzer C, Sperk G. Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br. J. Pharmacol. 1994;113:737–740
  23. Gutiérrez-Mariscal M, de Gortari P, López-Rubalcava C, Martínez A, Joseph-Bravo P. Analysis of the anxiolytic-like effect of TRH and the response of amygdalar TRHergic neurons in anxiety. Psychoneuroendocrinology. 2008;33:198–213
  24. Heuer H, Schäfer MK, Bauer K. Thyrotropin-releasing hormone (TRH), a signal peptide of the central nervous system. Acta Med. Austriaca. 1999;26:119–122
  25. Hollenberg AN. The role of the thyrotropin-releasing hormone (TRH) neuron as a metabolic sensor. Thyroid. 2008;18:131–139
  26. Hrabovszky E, Wittmann G, Turi GF, Liposits Z, Fekete C. Hypophysiotropic thyrotropin-releasing hormone and corticotropin-releasing hormone neurons of the rat contain vesicular glutamate transporter-2. Endocrinology. 2005;146:341–347
  27. Jantas D, Lason W. Protective effect of memantine against doxorubicin toxicity in primary neuronal cell cultures: influence a development stage. Neurotox. Res. 2009;15:24–37
  28. Jantas-Skotniczna D, Kajta M, Lason W. Memantine attenuates staurosporine-induced activation of caspase-3 and LDH release in mouse primary neuronal cultures. Brain Res. 2006;1069:145–153
  29. Jaworska-Feil L, Kajta M, Budziszewska B, Leśkiewicz M, Lasoń W. Protective effects of TRH and its stable analogue, RGH-2202, on kainate-induced seizures and neurotoxicity in rodents. Epilepsy Res. 2001;43:67–73
  30. Jaworska-Feil L, Turchan J, Przewłocka B, Budziszewska B, Leśkiewicz M, Lasoń W. Effects of pilocarpine- and kainate-induced seizures on thyrotropin-releasing hormone biosynthesis and receptors in the rat brain. J. Neural. Transm. 1999;106:395–407
  31. Jaworska-Feil L, Turchan J, Przewłocka B, Budziszewska B, Leśkiewicz M, Lasoń W. Effects of pentylenetetrazole-induced kindling on thyrotropin-releasing hormone biosynthesis and receptors in rat brain. Neuroscience. 1999;90:695–704
  32. Jensen JB, Schousboe A, Pickering DS. AMPA receptor mediated excitotoxicity in neocortical neurons is developmentally regulated and dependent upon receptor desensitization. Neurochem. Int. 1998;32:505–513
  33. Kajta M, Trotter A, Lasoń W, Beyer C. Effect of NMDA on staurosporine-induced activation of caspase-3 and LDH release in mouse neocortical and hippocampal cells. Brain Res. Dev. Brain Res. 2005;160:40–52
  34. Kajta M, Marszał M, Kubera M, Lasoń W. Effects of estrone on quisqualate-induced toxicity in primary cultures of rat cortical neurons. J. Physiol. Pharmacol. 2005;56:233–245
  35. Kaytor MD, Orr HT. The GSK3 beta signaling cascade and neurodegenerative disease. Curr. Opin. Neurobiol. 2002;12:275–278
  36. Koenig ML, Sgarlat CM, Yourick DL, Long JB, Meyerhoff JL. In vitro neuroprotection against glutamate-induced toxicity by pGlu-Glu-Pro-NH(2) (EEP). Peptides. 2001;22:2091–2097
  37. Koh IY, Wie MB, Gwag BJ, Sensi SL, Canzoniero LMT, Demaro J, et al. Staurosporine-induced neuronal apoptosis. Exp. Neurol. 1995;135:153–159
  38. Kramer RH, Kaczmarek LK, Levitan ES. Neuropeptide inhibition of voltage-gated calcium channels mediated by mobilization of intracellular calcium. Neuron. 1991;6:557–563
  39. Kreider MS, Wolfinger BL, Winokur A. Systemic administration of kainic acid produces elevations in TRH in rat central nervous system. Regul. Pept. 1990;28:83–93
  40. Kubek MJ, Knoblach SM, Sharif NA, Burt DR, Buterbaugh GG, Fuson KS. Thyrotropin-releasing hormone gene expression and receptors are differentially modified in limbic foci by seizures. Ann. Neurol. 1993;33:70–76
  41. Landshamer S, Hoehn M, Barth N, Duvezin-Caubet S, Schwake G, Tobaben S, et al. Bid-induced release of AIF from mitochondria causes immediate neuronal cell death. Cell Death Differ. 2008;15:1553–1563
  42. Lankiewicz S, Marc Luetjens C, Truc Bui N. Activation of calpain I converts excitotoxic neuronal death into a caspase-independent cell death. J. Biol. Chem. 2000;275:17064–17071
  43. Liu D, Slevin JR, Lu C, Chan SL, Hansson M, Elmér E, et al. Involvement of mitochondrial K+ release and cellular efflux in ischemic and apoptotic neuronal death. J. Neurochem. 2003;86:966–979
  44. Luo HR, Hattori H, Hossain MA, Hester L, Huang Y, Lee-Kwon W, et al. Akt as a mediator of cell death. Proc. Natl. Acad. Sci. USA. 2003;100:11712–11717
  45. Luo L, Stopa EG. Thyrotropin releasing hormone inhibits tau phosphorylation by dual signaling pathways in hippocampal neurons. J. Alzheimers Dis. 2004;6:527–536
  46. Luo L, Yano N, Mao Q, Jackson IM, Stopa EG. Thyrotropin releasing hormone (TRH) in the hippocampus of Alzheimer patients. J. Alzheimers Dis. 2002;4:97–103
  47. Lysko PG, Webb CL, Yue TL, Gu JL, Feuerstein G. Neuroprotective effects of tetrodotoxin as a Na+ channel modulator and glutamate release inhibitor in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke. 1994;25:2476–2482
  48. Miloso M, Scuteri A, Foudah D, Tredici G. MAPKs as mediators of cell fate determination: an approach to neurodegenerative diseases. Curr. Med. Chem. 2008;15:538–548
  49. Monga V, Meena CL, Kaur N, Jain R. Chemistry and biology of thyrotropin-releasing hormone (TRH) and its analogs. Curr. Med. Chem. 2008;15:2718–2733
  50. Moore JD, Rothwell NJ, Gibson RM. Involvement of caspases and calpains in cerebrocortical neuronal cell death is stimulus-dependent. Br. J. Pharmacol. 2002;135:1069–1077
  51. Movsesyan VA, Stoica BA, Faden AI. MGLuR5 activation reduces beta-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor. J. Neurochem. 2004;89:1528–1536
  52. Nie Y, Schoepp DD, Klaunig JE, Yard M, Lahiri DK, Kubek MJ. Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro. Brain Res. 2005;1054:45–54
  53. Noda Y, Furukawa K, Kohayakawa H, Oka M. Effects of RGH-2202 on behavioral deficits after focal cerebral ischemia in rats. Pharmacol. Biochem. Behav. 1995;52:695–699
  54. Ogita K, Okuda H, Watanabe M, Nagashima R, Sugiyama C, Yoneda Y. In vivo treatment with the K+ channel blocker 4-aminopyridine protects against kainate-induced neuronal cell death through activation of NMDA receptors in murine hippocampus. Neuropharmacology. 2005;48:810–821
  55. Oka M, Itoh Y, Ukai Y, Yoshikuni Y, Kimura K. Protein kinases are involved in prolonged acetylcholine release from rat hippocampus induced by thyrotropin-releasing hormone analogue NS-3. J. Neurochem. 1996;66:1889–1893
  56. Pitts LH, Ross A, Chase GA, Faden AI. Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries. J. Neurotrauma. 1995;12:235–243
  57. Pizzi M, Boroni F, Benarese M, Moraitis C, Memo M, Spano P. Neuroprotective effect of thyrotropin-releasing hormone against excitatory amino acid-induced cell death in hippocampal slices. Eur. J. Pharmacol. 1999;370:133–137
  58. Prakash KR, Tang Y, Kozikowski AP, Flippen-Anderson JL, Knoblach SM, Faden AI. Synthesis and biological activity of novel neuroprotective diketopiperazines. Bioorg. Med. Chem. 2002;10:3043–3048
  59. Prokai L, Prokai-Tatrai K, Zharikova AD, Nguyen V, Perjesi P, Stevens SM. Centrally acting and metabolically stable thyrotropin-releasing hormone analogues by replacement of histidine with substituted pyridinium. J. Med. Chem. 2004;47:6025–6033
  60. Przewlocka B, Labuz D, Mika J, Lipkowski A, van Luijtelaar G, Coenen A, et al. Protective effects of TRH and its analogues in chemical and genetic models of seizures. Pol. J. Pharmacol. 1997;49:373–378
  61. Puniak MA, Freeman GM, Agresta CA, Van Newkirk L, Barone CA, Salzman SK. Comparison of a serotonin antagonist, opioid antagonist, and TRH analog for the acute treatment of experimental spinal trauma. J. Neurotrauma. 1991;8:193–203
  62. Qiu JH, Asai A, Chi S, Saito N, Hamada H, Kirino T. Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J. Neurosci. 2000;20:259–265
  63. Rajput SK, Krishnamoorthy S, Pawar C, Kaur N, Monga V, Meena CL, et al. Antiepileptic potential and behavioral profile of L-pGlu-(2-propyl)-L-His-L-ProNH2, a newer thyrotropin-releasing hormone analog. Epilepsy Behav. 2009;14:48–53
  64. Sarkadi A, Kárpáti E. TRH analogs at Gedeon Richter Ltd.: highlights of experimental and clinical efficacy of posatirelin. Acta Pharm. Hung. 2002;72:62–68
  65. Schurr A. Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels. Curr. Drug. Targets. 2004;5:603–618
  66. Shinozuka K, Shimoura K, Hattori K. Effects of thyrotropin-releasing hormone and its analogue, NS-3, on blood pressure, heart rate, and serum catecholamine levels in rats. Gen. Pharmacol. 1997;28:209–214
  67. Ueda M, Iida Y, Kitamura Y, Kawashima H, Ogawa M, Magata Y, et al. 5-Iodo-A-85380, a specific ligand for alpha 4 beta 2 nicotinic acetylcholine receptors, prevents glutamate neurotoxicity in rat cortical cultured neurons. Brain Res. 2008;1199:46–52
  68. Urayama A, Yamada S, Hirano K, Deguchi Y, Kimura R. Brain receptor binding characteristics and pharmacokinetic-pharmacodynamic analysis of thyrotropin-releasing hormone analogues. Life Sci. 2001;70:647–657
  69. Urayama A, Yamada S, Ohmori Y, Deguchi Y, Uchida S, Kimura R. Blood–brain permeability of [3H]-(3-methyl-His2)thyrotropin-releasing hormone (MeTRH) in mice. effects of TRH and its analogues. Drug. Metab. Pharmacokinet. 2003;18:310–318
  70. Urayama A, Yamada S, Deguchi Y, Ohmori Y, Kimura R. Studies on the transport of thyrotropin-releasing hormone (TRH) analogues in Caco-2 cell monolayers. J. Pharm. Pharmacol. 2003;55:603–608
  71. Veronesi MC, Yard M, Jackson J, Lahiri DK, Kubek MJ. An analog of thyrotropin-releasing hormone (TRH) is neuroprotective against glutamate-induced toxicity in fetal rat hippocampal neurons in vitro. Brain Res. 2007;1128:79–85
  72. Wetzel M, Tibbitts J, Rosenberg GA, Cunningham LA. Vulnerability of mouse cortical neurons to doxorubicin-induced apoptosis is strain-dependent and is correlated with mRNAs encoding Fas, Fas-ligand, and metalloprotenases. Apoptosis. 2004;9:649–656
  73. Yarbrough GG. Fundamental molecular mechanism of the CNS effects of TRH. Trends Pharmacol. Sci. 2003;24:617–618
  74. Zhang Y, Bhavnani BR. Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens. BMC Neurosci. 2006;15:7–49

PII: S0143-4179(09)00082-1

doi: 10.1016/j.npep.2009.07.002

Neuropeptides
Volume 43, Issue 5 , Pages 371-385 , October 2009

Article Tools

* Image Usage & Resolution